Watch the Dallas Symposium LIVE, and fundraiser auction
Ticket proceeds support mindat.org! - click here...
Log InRegister
Quick Links : The Mindat ManualThe Rock H. Currier Digital LibraryMindat Newsletter [Free Download]
Home PageAbout MindatThe Mindat ManualHistory of MindatCopyright StatusWho We AreContact UsAdvertise on Mindat
Donate to MindatCorporate SponsorshipSponsor a PageSponsored PagesMindat AdvertisersAdvertise on Mindat
Learning CenterWhat is a mineral?The most common minerals on earthInformation for EducatorsMindat ArticlesThe ElementsThe Rock H. Currier Digital LibraryGeologic Time
Minerals by PropertiesMinerals by ChemistryAdvanced Locality SearchRandom MineralRandom LocalitySearch by minIDLocalities Near MeSearch ArticlesSearch GlossaryMore Search Options
Search For:
Mineral Name:
Locality Name:
Keyword(s):
 
The Mindat ManualAdd a New PhotoRate PhotosLocality Edit ReportCoordinate Completion ReportAdd Glossary Item
Mining CompaniesStatisticsUsersMineral MuseumsClubs & OrganizationsMineral Shows & EventsThe Mindat DirectoryDevice SettingsThe Mineral Quiz
Photo SearchPhoto GalleriesSearch by ColorNew Photos TodayNew Photos YesterdayMembers' Photo GalleriesPast Photo of the Day GalleryPhotography

(2013, July) Reactions Weekly Vol. 1459 (1) Springer Science and Business Media LLC

Advanced
   -   Only viewable:
Reference TypeJournal (issue)
JournalReactions Weekly
Year2013 (July)Volume1459
Issue1
PublisherSpringer Science and Business Media LLC
Mindat Ref. ID13304040Long-form Identifiermindat:1:5:13304040:3
GUID0
Full Reference(2013, July) Reactions Weekly Vol. 1459 (1) Springer Science and Business Media LLC
Plain Text(2013, July) Reactions Weekly Vol. 1459 (1) Springer Science and Business Media LLC
In(2013) Reactions Weekly Vol. 1459. Springer Science and Business Media LLC

Contains

(2013) Should all recipients of contaminated methylprednisolone injection be screened?. Reactions Weekly, 1459 (1) 1 doi:10.1007/s40278-013-4202-7
(2013) Saxagliptin meets primary safety endpoint in large, phase IV trial. Reactions Weekly, 1459 (1) 2 doi:10.1007/s40278-013-4203-6
(2013) Nationwide pattern of questionable prescribing in the US. Reactions Weekly, 1459 (1) 2 doi:10.1007/s40278-013-4204-5
(2013) Dabigatran safe for long-term treatment of AF. Reactions Weekly, 1459 (1) 2 doi:10.1007/s40278-013-4205-4
(2013) Desvenlafaxine: tapering versus abrupt discontinuation. Reactions Weekly, 1459 (1) 3 doi:10.1007/s40278-013-4206-3
(2013) Cariprazine linked to increased risk of EPS. Reactions Weekly, 1459 (1) 3 doi:10.1007/s40278-013-4207-2
(2013) Takeda withdraws application for Omontys in Europe. Reactions Weekly, 1459 (1) 3 doi:10.1007/s40278-013-4208-1
(2013) Allergic reactions to IV iron meds, close monitoring required. Reactions Weekly, 1459 (1) 3 doi:10.1007/s40278-013-4209-0
(2013) Anaphylactic reactions to chlorhexidine. Reactions Weekly, 1459 (1) 4 doi:10.1007/s40278-013-4210-7
(2013) Placenta-based cell therapy clinical trial placed on hold. Reactions Weekly, 1459 (1) 4 doi:10.1007/s40278-013-4211-6
(2013) Lilly stops phase II β-secretase inhibitor trial. Reactions Weekly, 1459 (1) 4 doi:10.1007/s40278-013-4212-5
(2013) EPVC establishes first regional centre, in Alexandria. Reactions Weekly, 1459 (1) 4 doi:10.1007/s40278-013-4213-4
(2013) CHMP calls for major restrictions to the use of ergot derivatives. Reactions Weekly, 1459 (1) 4 doi:10.1007/s40278-013-4214-3
(2013) Albendazole. Reactions Weekly, 1459 (1) 5 doi:10.1007/s40278-013-4215-2
(2013) Adalimumab. Reactions Weekly, 1459 (1) 5 doi:10.1007/s40278-013-4216-1
(2013) Aciclovir. Reactions Weekly, 1459 (1) 5 doi:10.1007/s40278-013-4217-0
(2013) Adalimumab. Reactions Weekly, 1459 (1) 5 doi:10.1007/s40278-013-4218-z
(2013) Agaricus HCC. Reactions Weekly, 1459 (1) 5 doi:10.1007/s40278-013-4219-y
(2013) Alendronic acid. Reactions Weekly, 1459 (1) 6 doi:10.1007/s40278-013-4222-3
(2013) Amisulpride. Reactions Weekly, 1459 (1) 6 doi:10.1007/s40278-013-4223-2
(2013) Amoxicillin. Reactions Weekly, 1459 (1) 6 doi:10.1007/s40278-013-4220-5
(2013) Alendronic acid/denosumab. Reactions Weekly, 1459 (1) 6 doi:10.1007/s40278-013-4221-4
(2013) Antiarrhythmics. Reactions Weekly, 1459 (1) 7 doi:10.1007/s40278-013-4224-1
(2013) Antineoplastics. Reactions Weekly, 1459 (1) 7 doi:10.1007/s40278-013-4225-0
(2013) Antiretrovirals/BCG vaccine. Reactions Weekly, 1459 (1) 7 doi:10.1007/s40278-013-4226-z
(2013) Antineoplastics. Reactions Weekly, 1459 (1) 7 doi:10.1007/s40278-013-4227-y
(2013) Amphotericin B liposomal. Reactions Weekly, 1459 (1) 7 doi:10.1007/s40278-013-4228-x
(2013) Arsenic trioxide. Reactions Weekly, 1459 (1) 8 doi:10.1007/s40278-013-4229-9
(2013) Aripiprazole overdose. Reactions Weekly, 1459 (1) 8 doi:10.1007/s40278-013-4230-3
(2013) Arsenic trioxide overdose. Reactions Weekly, 1459 (1) 8 doi:10.1007/s40278-013-4231-2
(2013) Antituberculars. Reactions Weekly, 1459 (1) 8 doi:10.1007/s40278-013-4232-1
(2013) Atomoxetine/varenicline. Reactions Weekly, 1459 (1) 9 doi:10.1007/s40278-013-4233-0
(2013) Aspirin/clopidogrel. Reactions Weekly, 1459 (1) 9 doi:10.1007/s40278-013-4234-z
(2013) Azathioprine. Reactions Weekly, 1459 (1) 9 doi:10.1007/s40278-013-4235-y
(2013) Aspirin. Reactions Weekly, 1459 (1) 9 doi:10.1007/s40278-013-4236-x
(2013) Calcium monoethyl fumarate/dimethyl fumarate. Reactions Weekly, 1459 (1) 10 doi:10.1007/s40278-013-4237-9
(2013) Capecitabine. Reactions Weekly, 1459 (1) 10 doi:10.1007/s40278-013-4238-8
(2013) Azathioprine/methotrexate/prednisolone. Reactions Weekly, 1459 (1) 10 doi:10.1007/s40278-013-4239-7
(2013) Busulfan. Reactions Weekly, 1459 (1) 10 doi:10.1007/s40278-013-4240-1
(2013) Capecitabine/trastuzumab. Reactions Weekly, 1459 (1) 11 doi:10.1007/s40278-013-4241-0
(2013) Cetuximab/paclitaxel. Reactions Weekly, 1459 (1) 11 doi:10.1007/s40278-013-4242-z
(2013) Ceftriaxone. Reactions Weekly, 1459 (1) 11 doi:10.1007/s40278-013-4243-y
(2013) Carbamazepine. Reactions Weekly, 1459 (1) 11 doi:10.1007/s40278-013-4244-x
(2013) Ciclosporin/everolimus. Reactions Weekly, 1459 (1) 12 doi:10.1007/s40278-013-4245-9
(2013) Ciclosporin/clobetasol. Reactions Weekly, 1459 (1) 12 doi:10.1007/s40278-013-4246-8
(2013) Ciclosporin/prednisolone. Reactions Weekly, 1459 (1) 12 doi:10.1007/s40278-013-4247-7
(2013) Ciclosporin/prednisone. Reactions Weekly, 1459 (1) 12 doi:10.1007/s40278-013-4248-6
(2013) Clarithromycin/rabeprazole interaction. Reactions Weekly, 1459 (1) 13 doi:10.1007/s40278-013-4249-5
(2013) Clozapine. Reactions Weekly, 1459 (1) 13 doi:10.1007/s40278-013-4250-z
(2013) Clarithromycin/cyclophosphamide/prednisolone. Reactions Weekly, 1459 (1) 13 doi:10.1007/s40278-013-4251-y
(2013) Clozapine. Reactions Weekly, 1459 (1) 13 doi:10.1007/s40278-013-4252-x
(2013) Colecalciferol/vitamin D/rifampicin. Reactions Weekly, 1459 (1) 14 doi:10.1007/s40278-013-4253-9
(2013) Cotrimoxazole. Reactions Weekly, 1459 (1) 14 doi:10.1007/s40278-013-4254-8
(2013) Cyproterone. Reactions Weekly, 1459 (1) 14 doi:10.1007/s40278-013-4255-7
(2013) Dabigatran etexilate. Reactions Weekly, 1459 (1) 15 doi:10.1007/s40278-013-4256-6
(2013) Dabigatran etexilate. Reactions Weekly, 1459 (1) 15 doi:10.1007/s40278-013-4257-5
(2013) Dabigatran etexilate. Reactions Weekly, 1459 (1) 15 doi:10.1007/s40278-013-4258-4
(2013) Dabigatran etexilate. Reactions Weekly, 1459 (1) 15 doi:10.1007/s40278-013-4259-3
(2013) Deferiprone. Reactions Weekly, 1459 (1) 16 doi:10.1007/s40278-013-4260-x
(2013) Decitabine. Reactions Weekly, 1459 (1) 16 doi:10.1007/s40278-013-4261-9
(2013) Dasatinib. Reactions Weekly, 1459 (1) 16 doi:10.1007/s40278-013-4262-8
(2013) Deflazacort/leflunomide/methotrexate. Reactions Weekly, 1459 (1) 16 doi:10.1007/s40278-013-4263-7
(2013) Dapsone/prednisolone. Reactions Weekly, 1459 (1) 16 doi:10.1007/s40278-013-4264-6
(2013) Dexamethasone. Reactions Weekly, 1459 (1) 17 doi:10.1007/s40278-013-4265-5
(2013) Denosumab. Reactions Weekly, 1459 (1) 17 doi:10.1007/s40278-013-4266-4
(2013) Dexamethasone. Reactions Weekly, 1459 (1) 17 doi:10.1007/s40278-013-4267-3
(2013) Diclofenac. Reactions Weekly, 1459 (1) 17 doi:10.1007/s40278-013-4268-2
(2013) Dicycloverine/dextropropoxyphene/paracetamol abuse. Reactions Weekly, 1459 (1) 18 doi:10.1007/s40278-013-4269-1
(2013) Diphtheria tetanus and pertussis vaccine. Reactions Weekly, 1459 (1) 18 doi:10.1007/s40278-013-4270-8
(2013) Digoxin. Reactions Weekly, 1459 (1) 18 doi:10.1007/s40278-013-4271-7
(2013) Doxorubicin/iohexol. Reactions Weekly, 1459 (1) 19 doi:10.1007/s40278-013-4272-6
(2013) Droperidol. Reactions Weekly, 1459 (1) 19 doi:10.1007/s40278-013-4273-5
(2013) Erlotinib. Reactions Weekly, 1459 (1) 19 doi:10.1007/s40278-013-4274-4
(2013) Etodolac. Reactions Weekly, 1459 (1) 19 doi:10.1007/s40278-013-4275-3
(2013) Drotrecogin-α. Reactions Weekly, 1459 (1) 19 doi:10.1007/s40278-013-4276-2
(2013) Everolimus/octreotide. Reactions Weekly, 1459 (1) 20 doi:10.1007/s40278-013-4277-1
(2013) Fluticasone propionate. Reactions Weekly, 1459 (1) 20 doi:10.1007/s40278-013-4278-0
(2013) Fentanyl/fluoxetine/pethidine interaction. Reactions Weekly, 1459 (1) 20 doi:10.1007/s40278-013-4279-z
(2013) Foscarnet. Reactions Weekly, 1459 (1) 20 doi:10.1007/s40278-013-4280-6
(2013) Hydrocodone/paracetamol withdrawal. Reactions Weekly, 1459 (1) 21 doi:10.1007/s40278-013-4281-5
(2013) Gadobutrol. Reactions Weekly, 1459 (1) 21 doi:10.1007/s40278-013-4282-4
(2013) Human papillomavirus vaccine recombinant quadrivalent. Reactions Weekly, 1459 (1) 21 doi:10.1007/s40278-013-4283-3
(2013) Foscarnet. Reactions Weekly, 1459 (1) 21 doi:10.1007/s40278-013-4284-2
(2013) Gemcitabine. Reactions Weekly, 1459 (1) 21 doi:10.1007/s40278-013-4285-1
(2013) Ibuprofen. Reactions Weekly, 1459 (1) 22 doi:10.1007/s40278-013-4286-0
(2013) Immune globulin. Reactions Weekly, 1459 (1) 22 doi:10.1007/s40278-013-4287-z
(2013) Hydroxychloroquine. Reactions Weekly, 1459 (1) 22 doi:10.1007/s40278-013-4288-y
(2013) Hydroxychloroquine. Reactions Weekly, 1459 (1) 22 doi:10.1007/s40278-013-4289-x
(2013) Infliximab. Reactions Weekly, 1459 (1) 22 doi:10.1007/s40278-013-4290-4
(2013) Influenza virus vaccine. Reactions Weekly, 1459 (1) 23 doi:10.1007/s40278-013-4291-3
(2013) Influenza A virus vaccine-H1N1. Reactions Weekly, 1459 (1) 23 doi:10.1007/s40278-013-4292-2
(2013) Interleukin-2. Reactions Weekly, 1459 (1) 23 doi:10.1007/s40278-013-4293-1
(2013) Influenza A virus vaccine-H1N1. Reactions Weekly, 1459 (1) 23 doi:10.1007/s40278-013-4294-0
(2013) Ipilimumab. Reactions Weekly, 1459 (1) 24 doi:10.1007/s40278-013-4295-z
(2013) Ipilimumab. Reactions Weekly, 1459 (1) 24 doi:10.1007/s40278-013-4296-y
(2013) Lenalidomide. Reactions Weekly, 1459 (1) 24 doi:10.1007/s40278-013-4297-x
(2013) Levofloxacin. Reactions Weekly, 1459 (1) 25 doi:10.1007/s40278-013-4298-9
(2013) Levetiracetam. Reactions Weekly, 1459 (1) 25 doi:10.1007/s40278-013-4299-8
(2013) Levonorgestrel. Reactions Weekly, 1459 (1) 25 doi:10.1007/s40278-013-4300-6
(2013) Levodopa/carbidopa. Reactions Weekly, 1459 (1) 25 doi:10.1007/s40278-013-4301-5
(2013) Lidocaine. Reactions Weekly, 1459 (1) 25 doi:10.1007/s40278-013-4302-4
(2013) Mesalazine. Reactions Weekly, 1459 (1) 26 doi:10.1007/s40278-013-4303-3
(2013) Mercaptopurine. Reactions Weekly, 1459 (1) 26 doi:10.1007/s40278-013-4304-2
(2013) Lidocaine. Reactions Weekly, 1459 (1) 26 doi:10.1007/s40278-013-4305-1
(2013) Methotrexate overdose. Reactions Weekly, 1459 (1) 27 doi:10.1007/s40278-013-4306-0
(2013) Methotrexate. Reactions Weekly, 1459 (1) 27 doi:10.1007/s40278-013-4307-z
(2013) Mesalazine. Reactions Weekly, 1459 (1) 27 doi:10.1007/s40278-013-4308-y
(2013) Methotrexate. Reactions Weekly, 1459 (1) 27 doi:10.1007/s40278-013-4309-x
(2013) Natalizumab. Reactions Weekly, 1459 (1) 28 doi:10.1007/s40278-013-4310-4
(2013) Methylprednisolone. Reactions Weekly, 1459 (1) 28 doi:10.1007/s40278-013-4311-3
(2013) Methylprednisolone. Reactions Weekly, 1459 (1) 28 doi:10.1007/s40278-013-4312-2
(2013) Mirtazapine/ondansetron interaction. Reactions Weekly, 1459 (1) 28 doi:10.1007/s40278-013-4313-1
(2013) Methylphenidate. Reactions Weekly, 1459 (1) 28 doi:10.1007/s40278-013-4314-0
(2013) Natalizumab. Reactions Weekly, 1459 (1) 29 doi:10.1007/s40278-013-4315-z
(2013) Nifedipine. Reactions Weekly, 1459 (1) 29 doi:10.1007/s40278-013-4316-y
(2013) Nifedipine. Reactions Weekly, 1459 (1) 29 doi:10.1007/s40278-013-4317-x
(2013) Ofloxacin/ornidazole. Reactions Weekly, 1459 (1) 29 doi:10.1007/s40278-013-4318-9
(2013) Olanzapine. Reactions Weekly, 1459 (1) 29 doi:10.1007/s40278-013-4319-8
(2013) Oxymorphone abuse. Reactions Weekly, 1459 (1) 29 doi:10.1007/s40278-013-4320-2
(2013) Pamidronic acid. Reactions Weekly, 1459 (1) 30 doi:10.1007/s40278-013-4321-1
(2013) Pamidronic acid. Reactions Weekly, 1459 (1) 30 doi:10.1007/s40278-013-4322-0
(2013) Pegfilgrastim. Reactions Weekly, 1459 (1) 30 doi:10.1007/s40278-013-4323-z
(2013) Papaverine. Reactions Weekly, 1459 (1) 30 doi:10.1007/s40278-013-4324-y
(2013) Phenol. Reactions Weekly, 1459 (1) 31 doi:10.1007/s40278-013-4325-x
(2013) Penicillamine. Reactions Weekly, 1459 (1) 31 doi:10.1007/s40278-013-4326-9
(2013) Pentazocine. Reactions Weekly, 1459 (1) 31 doi:10.1007/s40278-013-4327-8
(2013) Phenytoin. Reactions Weekly, 1459 (1) 31 doi:10.1007/s40278-013-4328-7
(2013) Potassium aminobenzoate. Reactions Weekly, 1459 (1) 32 doi:10.1007/s40278-013-4329-6
(2013) Pregabalin. Reactions Weekly, 1459 (1) 32 doi:10.1007/s40278-013-4330-0
(2013) Prednisone/ruxolitinib. Reactions Weekly, 1459 (1) 32 doi:10.1007/s40278-013-4331-z
(2013) Potassium chloride/spironolactone. Reactions Weekly, 1459 (1) 32 doi:10.1007/s40278-013-4332-y
(2013) Raltegravir. Reactions Weekly, 1459 (1) 33 doi:10.1007/s40278-013-4333-x
(2013) Proxymetacaine abuse. Reactions Weekly, 1459 (1) 33 doi:10.1007/s40278-013-4334-9
(2013) Regadenoson. Reactions Weekly, 1459 (1) 33 doi:10.1007/s40278-013-4335-8
(2013) Prothrombin complex concentrate. Reactions Weekly, 1459 (1) 33 doi:10.1007/s40278-013-4336-7
(2013) Ropinirole. Reactions Weekly, 1459 (1) 34 doi:10.1007/s40278-013-4337-6
(2013) Strontium ranelate. Reactions Weekly, 1459 (1) 34 doi:10.1007/s40278-013-4338-5
(2013) Sorafenib. Reactions Weekly, 1459 (1) 34 doi:10.1007/s40278-013-4339-4
(2013) Rituximab. Reactions Weekly, 1459 (1) 34 doi:10.1007/s40278-013-4340-y
(2013) Sorafenib. Reactions Weekly, 1459 (1) 34 doi:10.1007/s40278-013-4341-x
(2013) Sunitinib. Reactions Weekly, 1459 (1) 35 doi:10.1007/s40278-013-4342-9
(2013) Tacrolimus. Reactions Weekly, 1459 (1) 35 doi:10.1007/s40278-013-4343-8
(2013) Telaprevir. Reactions Weekly, 1459 (1) 35 doi:10.1007/s40278-013-4344-7
(2013) Vancomycin. Reactions Weekly, 1459 (1) 36 doi:10.1007/s40278-013-4345-6
(2013) TJ 54. Reactions Weekly, 1459 (1) 36 doi:10.1007/s40278-013-4346-5
(2013) Temozolomide. Reactions Weekly, 1459 (1) 36 doi:10.1007/s40278-013-4347-4
(2013) Triamcinolone. Reactions Weekly, 1459 (1) 36 doi:10.1007/s40278-013-4348-3
(2013) Venlafaxine withdrawal. Reactions Weekly, 1459 (1) 37 doi:10.1007/s40278-013-4349-2
(2013) Vancomycin. Reactions Weekly, 1459 (1) 37 doi:10.1007/s40278-013-4350-9
(2013) Vemurafenib. Reactions Weekly, 1459 (1) 37 doi:10.1007/s40278-013-4351-8
(2013) Zoledronic acid. Reactions Weekly, 1459 (1) 38 doi:10.1007/s40278-013-4352-7
(2013) Warfarin. Reactions Weekly, 1459 (1) 38 doi:10.1007/s40278-013-4353-6
(2013) Warfarin. Reactions Weekly, 1459 (1) 38 doi:10.1007/s40278-013-4354-5
(2013) Warfarin. Reactions Weekly, 1459 (1) 38 doi:10.1007/s40278-013-4355-4

See Also

These are possibly similar items as determined by title/reference text matching only.

(2013, July) Reactions Weekly Vol. 1460 (1) Springer Science and Business Media LLC
(2013, July) Reactions Weekly Vol. 1461 (1) Springer Science and Business Media LLC
(2013, July) Reactions Weekly Vol. 1462 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1608 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1609 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1610 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1611 (1) Springer Science and Business Media LLC
(2016, July) Reactions Weekly Vol. 1612 (1) Springer Science and Business Media LLC
(2003, July) Reactions Weekly Vol. 961 (1) Springer Science and Business Media LLC
(2007, July) Reactions Weekly Vol. 1162 (1) Springer Science and Business Media LLC
(2014, July) Reactions Weekly Vol. 1508 (1) Springer Science and Business Media LLC
 
and/or  
Mindat.org is an outreach project of the Hudson Institute of Mineralogy, a 501(c)(3) not-for-profit organization.
Copyright © mindat.org and the Hudson Institute of Mineralogy 1993-2025, except where stated. Most political location boundaries are © OpenStreetMap contributors. Mindat.org relies on the contributions of thousands of members and supporters. Founded in 2000 by Jolyon Ralph.
To cite: Ralph, J., Von Bargen, D., Martynov, P., Zhang, J., Que, X., Prabhu, A., Morrison, S. M., Li, W., Chen, W., & Ma, X. (2025). Mindat.org: The open access mineralogy database to accelerate data-intensive geoscience research. American Mineralogist, 110(6), 833–844. doi:10.2138/am-2024-9486.
Privacy Policy - Terms & Conditions - Contact Us / DMCA issues - Report a bug/vulnerability Current server date and time: August 15, 2025 14:38:46
Go to top of page